The median duration of response was 9.2 months. The combination of atezolizumab and split doses of cisplatin and gemcitabine can produce durable responses in patients with locally advanced or ...
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a ...
Between January 2021 and March 2022, 66 patients were included. The OR was 48.5% (95% CI, 36 to 61), with seven (10.61%) patients experiencing complete response. The median DoR was 9.2 months (95% CI, ...
The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback